Leonhardt Ventures to Present Technology Showcase in National Harbor, Maryland just outside of the Heart Failure Society of America Annual Meeting - co-sponsored by HealthiosXchange - Tuesday, September 29th 11:45am
First combination implantable stem cell/growth factor pump + microcurrent regeneration stimulator for regenerating hearts will be presented - www.bioleonhardt.com + www.myostimpacers.com
Leonhardt Ventures Cal-X Stars Accelerator Scientific Advisory Board - http://calxstars.com/scientific-advisory-board/ and Business Advisory Board - http://calxstars.com/team-cal-x/
Innovations to be showcased include:
BioLeonhardt – http://www.bioleonhardt.com - first implantable, programmable, re-fillable stem cell pump in combination with microcurrent regeneration stimulation for treating advanced heart failure. Featuring combined utilization of MicroRNAs, time release SDF-1, various growth factors, nutrient hydrogel, cardiac stem cells, iPS cells and muscle progenitor stem cells all with programmed repeat deliveries.
MyoStim Pacers – http:/www.myostimpacers.com - world's first heart failure pacemaker designed to recruit reparative stem cells to damaged and weakened heart tissue.
MyoStim Peripheral - electrical stimulation device for treating critical limb ischemia and diabetic foot ulcers, pain relief - http://www.myostimpacers.com/microcurrent-stimulators.php - the MyoStim Axion device is U.S. FDA 510K market cleared for microcurrent treatments - FDA 510(k) K911814.
Note - BioLeonhardt and MyoStim are in the process of merging into one entity BioLeonhardt MyoStim.
Bioheart, Inc.* – http://www.bioheartinc.com - Phase III leader in applying adult muscle stem cells to treat advanced heart failure. Only cell type known to grow new contractile muscle in the depths of scar tissue. *Leonhardt Ventures founded Bioheart, Inc. in 1999 but now is only a minority position shareholder. Bioheart MyoCell in Phase II/III clinical trials beat placebo injections by 95.7 meters in exercise capacity improvement. 84% of Bioheart MyoCell treated patients have improved compared to only 16% of placebo or control patients in clinical studies since 2001.
BioPace – world's first biological pacemaker made entirely of living cells - http://www.leonhardtventures.com/biopace.php
CoroStim – world's first vibrational energy emitting pacemaker that prevents plaque formation in high risk coronary arteries.
CerebraCell - microcurrent based non-invasive energy system to for brain recovery following stroke or injury. Non-invasive cerebral aneurysm repair - http://leonhardtventures.com/cerebracell.php
Cardiobridge – http://www.cardiobridge.com - Highest flow rate 10FR circulatory support catheter pump in clinical testing for acute decompensating heart failure and high-risk PCI. Data on about 30 clinical patients will be presented + www.procyrion.com implantable system.
AortaCell – http://www.leonhardtventures.com/aortacell.php - Method and device to treat aortic aneurysms non-invasively and minimally invasively with devices that deliver focal wireless electrical energy to weakened aortic wall tissue that causes reparative autologous stem cells to home to that chosen treatment location which are then differentiated into smooth muscle thus reinforcing vessel wall strength.
EndoCell – Method and device for growing new endothelium lining of a damaged artery with a percutaneous needle catheter and endothelial progenitor cells.
Valvublator – Percutaneous catheter device for de-calcifying, cell sodding and regenerating heart valve leaflets so a patient may keep their own valve instead of getting an artificial implant - www.valvublator.com + http://www.leonhardtventures.com/valbulator.php Also tissue engineered heart valves.
HeartScore + NI Medical – Total Heart Failure Mangement System, heart failure and cardiovascular genomics, high fidelity monitoring and ECG analysis - www.heartscore.co + http://heartscore.co/heart-failure-management/ + www.heartgenomics.com + www.vivaquant.com HeartScore is also getting ready to publish the Top 100 Cardiovascular Innovations of 2015 eMagazine as well.
In addition to the above cardiovascular focused startups Leonhardt Ventures is incubating EyeCell (eye) - http://www.leonhardtventures.com/eyecell.php, Stem Cell Bra (breast www.stemcellbra.com) and DentaCell (dental gums) - http://www.leonhardtventures.com/denta-call.php, all utilizing microcurrent energy technology to direct stem cell and growth factor expression based healing.
Cal-X The California Stock Exchange TM - www.calxstockexchange.com - Preparing to the first social good impact and venture exchange in the USA with two listing boards. Plans to only list companies testing high on a scorecard for treating people, community and environment well, strong sense of purpose and with a strong innovation culture including INC. 500 type high year to year sales growth. The first part of this multi-year plan was the September 1, 2015 launch of The Cal-X 30 Social Good Impact Fund - https://www.motifinvesting.com/motifs/cal-x-30-social-good-impact-ind-j5wHgsYP - powered by the registered broker dealer Motif Investing of 30 curated social good impact stocks (already listed on NASDAQ, TMX Canada, OTC Markets or London AIM) with a heavy emphasis on the life sciences.
About Leonhardt Ventures: Since 1982 Leonhardt Ventures www.leonhardtventures.com has a strong history of inventing, developing, backing and bringing to market leadership products for treating heart and cardiovascular disease. Over 250,000 patients have been treated to date with Leonhardt inventions. In the 1980's the group developed market leadership in patented cardiovascular polyurethane balloon catheters including drug, stem cell and radiation delivery systems and also turn-key cath labs and CCUs. In the 1990s they developed over 20 additional devices including the first commercially successful stent graft for aortic aneurysm repair (TALENT – Taheri-Leonhardt Stent Graft) - SEE VIDEO https://vimeo.com/85232193 , the first percutaneous heart valve, intravascular lung catheter, the Pro-Cell intracavity stem cell delivery system and the MyoCath line of stem cell delivery catheters. Leonhardt patented inventions - http://patents.justia.com/inventor/howard-j-leonhardt - include the first heart failure pacemaker able to recruit reparative stem cells to damaged heart tissue (MyoStim Pacers - www.myostimpacers.com). In 2001 the team led the first in the world non-surgical case of stem cell repair of damaged heart muscle in a human patient with Bioheart MyoCell . That led to the first Phase II/III double blinded, randomized, placebo controlled trial for muscle stem cells growing new contractile muscle in post heart attack tissue in advanced heart failure patients – results published in the American Heart Journal Bioheart MyoCell patients 95.7 meters improvement in exercise capacity over placebo (minus 4 meters decline). The Leonhardt led team at BIoPace is preparing to complete the first ever biological pacemaker implantation made entirely of living cells in a human patient within the next 12-18 months. For more Leonhardt Ventures information - http://www.leonhardtventures.com/about-us.php 1Q 2015 Newsletter and 2014 Annual Report - http://us5.campaign-archive2.com/?u=3a3ec29e83782844c8ac560f9&id=158fdee643
About Cal-X Stars Business Accelerator, Inc www.calxstars.com : Leonhardt Ventures' organized the Cal-X Stars Business Accelerator, Inc. www.calxstars.com in 2013 to serve as a 5 year business accelerator for cardiovascular life science and social good impact innovations and startups. The Cal-X Stars 2015 class portfolio includes 15 cardiovascular and 15 social good impact startups.
About Healthiosxchange: The HealthiosXchange www.healthioxschange.com is the premiere investment marketplace dedicated exclusively to the global healthcare industry. Employing crowd funding as the cornerstone of a new paradigm in healthcare investing, the HealthiosXchange offers direct access to the broadest investment opportunities on a "Fee Free, Carry Free" basis in the most trusted online environment. The HealthiosXchange is an affiliate of Healthios Capital Markets, LLC., a FINRA-regulated broker dealer based in Chicago, with offices in Boston, London, Geneva, and Bangkok. Healthioxchange is a leader in self directed IRA financings with accredited investors into syndicates led by proven track record industry leaders.
Healthiosxchange is the official listing board for the the Cal-X Stars Business Accelerator, Inc. $15 million offering via 506D part C. This exemption allows general solicitation and up to 2000 accredited investors. Any potential investor's accredited status must be verified by a broker, lawyer, accountant or other verifiable means. Cal-X Stars Business Accelerator is incubating/accelerating by charter 15 cardiovascular and 15 social good impact startup innovations with intention to start auctioning them off to the highest bidders starting May 11th, 2018. By charter Cal-X Stars Business Accelerator, Inc will not accept any self directed IRA investments that exceed 10% of a person's IRA total portfolio and we recommend 5% due to the very high risk nature of investing in early stage cardiovascular and social good impact startups such as those incubating within the Cal-X Stars accelerator. Any potential investor should read all risk factors published in our private placement memorandum.